Last updated 2026-07-27
- Went public on NASDAQ (SLXN), Aug 2024
- Raised $13.2M Follow-on PO, Sep 2025
- Raised $9.6M Follow-on PO, Aug 2025
Total raised
$54.2M
Last: Public Offering 2025-09
Stage
Public
Founded
2008
Headcount
13
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
About
Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company's platform technology addresses difficult-to-treat solid tumors using RNA interference (RNAi) technology and targeted drug delivery. Their lead product candidate, SIL-204, consists of locally administered small interfering RNAs (siRNA) in an extended-release formulation for the first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy.
Funding history · 10 rounds · $54.2M total
2026-05
PIPE
$1.0M
2025-09
Follow-on PO
$13.2M
2025-08
PIPE
$1.8M
2025-08
Follow-on PO
$9.6M
2025-01
IPO
$5.0M
2025-01
PIPE
$3.3M
2024-08
Debt Financing
$2.0M
2015-09
A Round
$2.4M
★ Esperante Ventures
2014-03
Seed
$10.0M
★ Esperante Ventures
2009-08
Grant
$6.0M
Q&A
- What is Silexion Therapeutics' primary focus?
- Silexion Therapeutics is a clinical-stage biotechnology company focused on discovering and developing proprietary RNA interference (RNAi) treatments for KRAS-driven cancers.
- When did Silexion Therapeutics become publicly traded?
- Silexion Therapeutics became publicly traded on NASDAQ in August 2024, following a business combination with Moringa Acquisition Corp.
- What is Silexion Therapeutics' lead product candidate?
- Silexion Therapeutics' lead product candidate is SIL-204, which consists of locally administered small interfering RNAs (siRNA) in an extended-release formulation for the first-line treatment of locally advanced pancreatic cancer patients.
- What was a significant funding event for Silexion Therapeutics in August 2024?
- In August 2024, Silexion Therapeutics secured $17,000,000 through Debt Financing.
- What was the amount raised in Silexion Therapeutics' Public Offering in September 2025?
- In September 2025, Silexion Therapeutics raised $6,000,000 through a Public Offering.
- What is the current employee count for Silexion Therapeutics?
- Silexion Therapeutics has 13 employees, falling within the 11-50 employee bucket.
- What strategic partnership did Silexion Therapeutics announce in September 2025?
- In September 2025, Silexion Therapeutics announced a strategic partnership with AMS Advanced Medical Services GmbH, a contract research organization (CRO), to support its upcoming Phase 2/3 clinical trials for SIL204.
- What preclinical results did Silexion Therapeutics announce in September 2025 for SIL204?
- In September 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating high inhibition rates (83.5% to 99.7%) across eleven human cancer cell lines with various KRAS mutations, including the first evidence of activity in gastric cancer.
- What was a key regulatory achievement for Silexion Therapeutics in March 2026?
- In March 2026, Silexion Therapeutics received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.
- What collaboration did Silexion Therapeutics announce in December 2024?
- In December 2024, Silexion Therapeutics announced a collaboration with Evonik to develop an advanced siRNA formulation for its siRNA candidate, SIL-204, aimed at improving cancer treatment efficacy.
Team · 1
Amotz Shemi
Founder · Co-Founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
drug-discoverybiological-therapycanceroncologydrug-deliverypharmaceuticalscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | silexion.com/ |
|---|
Identifiers & details
| Legal name | Silexion Therapeutics Corp |
|---|---|
| Former names | Silenseed |
| Founded | 2008-11 |
| Employees (exact) | 13 |
| Market cap | $6.0M |
| Status reason | Public on NASDAQ on Aug, 2024; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2024-08 | NASDAQ | SLXN | |
| Public Offering | 2025-09 | NASDAQ | SLXN | $6.0M |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514207778 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-11-30 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 4 — annual_report (2), other (1), people (1) |
| Registered address | דרך אבא הלל 12 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-25 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-08-25 | דו~ח שנתי-הוספת בעל תפקיד |
| 2025-12-24 | עדכון כתובת ו/או מען דיגיטלי |
| 2025-08-21 | עדכון דירקטורים-הוספת דירקטור |